Lexaria Bioscience Corp
LEXX
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.31M
Close$
$-1.66
361.7% downside
Current Fair Value
361.7% downsideOvervalued by 361.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.31 Million |
|---|---|
| Enterprise Value | $7.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.66 |
| Beta | 0.36 |
| Outstanding Shares | 24,443,846 |
Return
| Return on Equity | -144.34% |
|---|---|
| Return on Assets | -146.90% |
| Return on Invested Capital | -151.38% |
Valuation & Multiples
| P/E Ratio | -1.54 |
|---|---|
| PEG | 3.32 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 19.77 |
| Enterprise Value to EBIT | -0.77 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 13, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationNext Earnings Call
Expected Date
July 13, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.10%▼ 1.86% |
|---|---|
| Total Invested | $1.17M▲ 10.80% |
| Investors Holding | 28▲ 7.00% |
ESG Score
No data
About Lexaria Bioscience Corp
3 employeesLexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness...